T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife has raised $110.0M in total funding. The most recent round was Series B. The last funding was announced in August 2021.
T-knife's investors include RA Capital Management, Andera Partners, EQT Life Sciences, Fidelity, Versant Ventures.
T-knife is headquartered in Berlin, Germany.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"T-knife — Funding & Investors." VCBacked, August 2, 2021, https://www.vcbacked.co/company/t-knife. Accessed August 14, 2026.
VCBacked. (2021). T-knife — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/t-knife
{{cite web |title=T-knife — Funding & Investors |url=https://www.vcbacked.co/company/t-knife |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated